1
Alotinib Plus Durvalumab-Platinum-Etoposide in First-line Treatment Extensive Small-cell Lung Cancer
Condition(s):SCLC, Extensive StageLast Updated:April 12, 2022Recruiting
First Line Treatment: 7368 Clinical Trials, Page 1 of 737
Hide Studies Not Open or Pending
2
The Clinical Research of Mesylate Apatinib Combined With Docetaxel and S-1 as the First-line Treatment of Metastatic Gastric Cancer
Condition(s):Metastatic Gastric CancerLast Updated:December 9, 2020Unknown status
3
Fruquintinib Combined With mFOLFOX6/FOLFIRI in First-line Treatment for Metastatic Colorectal Cancer
Condition(s):Metastatic Colorectal CancerLast Updated:October 26, 2022Recruiting
4
Fruquintinib and Serplulimab Combination Therapy for First-line Treatment of Non-clear Cell Renal Cell Carcinoma: A Prospective Multicenter Study
Condition(s):First-line Treatment of Non-clear Renal Cell CarcinomaLast Updated:April 26, 2023Not yet recruiting
5
Apatinib Plus Camrelizumab Combined With Docetaxel and S1 in First-line Treatment for Metastatic Gastric Cancer
Condition(s):Metastatic Gastric Adenocarcinoma; Metastatic Gastroesophageal Junction AdenocarcinomaLast Updated:May 17, 2021Recruiting
6
Efficacy and Safety of KN026 in Combination With HB1801 in the First-line Treatment of Subjects With HER2-positive Recurrent or Metastatic Breast Cancer.
Condition(s):First-line Treatment of HER2-positive Recurrent or Metastatic Breast CancerLast Updated:May 1, 2023Not yet recruiting
7
A Study of the First-line Treatment of Patients With Newly Diagnosed Transplant-ineligible Multiple Myeloma in Spain
Condition(s):Multiple MyelomaLast Updated:February 4, 2019Completed
8
Anlotinib Plus Sintilimab as First-line Treatment for Patients With Advanced Colorectal Cancer (APICAL-CR)
Condition(s):Colorectal Cancer; Immunotherapy; Anlotinib; Sintilimab; Chemo-free Therapy; First-line TreatmentLast Updated:December 30, 2020Unknown status
9
Ketogenic Diet for Patients Receiving First Line Treatment for Metastatic Renal Cell Carcinoma
Condition(s):Metastatic Renal CancerLast Updated:September 18, 2020Recruiting
10
SBRT for Oligoprogressive NSCLC After First Line Treatment With Immune Checkpoint Inhibitors
Condition(s):NSCLC Stage IVLast Updated:May 24, 2022Recruiting